Macrolide-Resistant <i>Mycoplasma pneumoniae</i> Infections among Children after COVID-19 Pandemic, Ohio, USA
Amy L. Leber, Tori Embry, Kathy Everhart, Jeanette Taveras, Sophonie J. Oyeniran, Huanyu Wang
Abstract
Mycoplasma pneumoniae infections decreased in Ohio, USA, during the COVID-19 pandemic but reemerged in 2023; >2,000 cases were reported during September 2023--September 2024. Of 995 M. pneumoniae-positive samples, 24 (2.4%) had mutations for macrolide-resistant M. pneumoniae (MRMp). MRMp rates are low but increasing. MRMp surveillance is crucial for monitoring antimicrobial resistance.
Topics & Concepts
Mycoplasma pneumoniaePandemicCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PneumoniaMicrobiologyMedicineBiologyOutbreakInfectious disease (medical specialty)Internal medicineDiseasePneumonia and Respiratory InfectionsRespiratory viral infections researchPneumocystis jirovecii pneumonia detection and treatment